Tekin 2004.

Methods	≥ 6‐Week dietary stabilisation period 3‐Month before‐and‐after study
Participants	38 men and women with hyperlipidaemia and CHD; LDL‐C > 135 mg/dL (3.49 mmol/L), TG < 300 mg/dL (3.39 mmol/L) Exclusion criteria: unstable angina pectoris, MI, stroke, coronary angioplasty, coronary bypass surgery, major surgery, anti‐inflammatory medication or anticoagulant usage before 6 months of study, cancer; liver, kidney or thyroid disease; SBP/DBP > 160/100 mmHg Baseline TC: 5.61 mmol/L (217 mg/dL) Baseline LDL‐C: 4.09 mmol/L (158 mg/dL) Baseline HDL‐C: 0.93 mmol/L (36 mg/dL) Baseline TG: 1.76 mmol/L (156 mg/dL)
Interventions	Atorvastatin 10 mg/d
Outcomes	Per cent change from baseline at 3 months of serum TC, LDL‐C, HDL‐C and TG
Notes	SDs were imputed
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Atorvastatin 10 mg/d; intervention was analysed, and as no placebo group was included for comparison, assessment of random sequence generation is not applicable
Allocation concealment (selection bias)	Unclear risk	Atorvastatin 10 mg/d; intervention was analysed, and as no placebo group was included for comparison, assessment of allocation concealment is not applicable
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Atorvastatin 10 mg/d; intervention was analysed, and as no placebo group was included for comparison, blinding status is not applicable
Incomplete outcome data (attrition bias) All outcomes	Low risk	Data on all participants were reported
Selective reporting (reporting bias)	Low risk	All lipid parameters were measured
Other bias	High risk	Pfizer funded the study; data may support bias for atorvastatin